In:
Blood Advances, American Society of Hematology, Vol. 2, No. 12 ( 2018-06-26), p. 1459-1469
Kurzfassung:
161533 TriKE–treated MDS NK cells proliferate and become activated to overcome tumor-induced NK cell dysfunction. IL-15 induces the inhibitory checkpoint TIGIT on NK cells, but not when IL-15 is presented in the context of 161533 TriKE.
Materialart:
Online-Ressource
ISSN:
2473-9529
,
2473-9537
DOI:
10.1182/bloodadvances.2017012369
Sprache:
Englisch
Verlag:
American Society of Hematology
Publikationsdatum:
2018
ZDB Id:
2876449-3